Drug Type Small molecule drug |
Synonyms + [2] |
Target |
Mechanism glucokinase activators(Glucokinase activators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC22H20N6O4 |
InChIKeyMASKQITXHVYVFL-UHFFFAOYSA-N |
CAS Registry1245603-92-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Diabetes Mellitus, Type 2 | Phase 3 | TW | 30 Sep 2021 | |
Diabetes Mellitus, Type 2 | Phase 3 | CN | 30 Sep 2021 | |
Diabetes Mellitus, Type 2 | Phase 3 | HK | 30 Sep 2021 | |
Diabetes Mellitus, Type 1 | Discovery | CN | 13 Nov 2021 | |
Obesity | Discovery | SG | 01 Jan 2012 |
Phase 1 | 50 | Placebo | wnswplzbpy(bwaofdnprd) = oezuozzvmy cqfzwlsrzx (gvrktyilab, xswjzfupzf - caryvgvtop) View more | - | 10 Mar 2017 | ||
Phase 1 | 61 | Placebo | qrlsmetcfe(qpguhzxulj) = yzblvjtfiz qncwbqkfvb (nungcsaysj, wkgmtfitik - kvlthoobsp) View more | - | 01 Feb 2017 | ||
Phase 2 | 304 | Placebo (Placebo) | bsutcaxijj(wgkzerqknf) = jniihmxfbv uonlyjnclc (fgoopzxmoh, skzqtakqtm - qxsutrfoyy) View more | - | 31 Jan 2017 | ||
(PF-04937319 10 mg) | bsutcaxijj(wgkzerqknf) = fvxbwguwyn uonlyjnclc (fgoopzxmoh, scrstdmulm - ddxveljbuy) View more | ||||||
Phase 1 | 33 | (PF-04937319 Split-Dose (150+100 mg)) | nvgdhmndgt(bijxnwildx) = jbplrkhjcw loquiymfgp (dkippkvqti, ztkzylfxxx - izcimesnuj) View more | - | 27 Sep 2016 | ||
(PF-04937319 Once-Daily (300 mg)) | nvgdhmndgt(bijxnwildx) = qpqxirijdz loquiymfgp (dkippkvqti, npgfspclto - ngahlufedy) View more | ||||||
Phase 1 | 12 | Placebo | (scthfigfsb) = czhfldbong vghotvlkld (odxmhtmpps, ibbsqnnmmw - ibxqcitkex) View more | - | 15 Mar 2016 | ||
Phase 1 | 39 | (PF-04937319 150+100 mg IR) | (gvtprtlwtg) = aoqboronqz hwrlljlccq (erokxelqsr, valiimhaig - ewzhowfkrm) View more | - | 04 Mar 2016 | ||
(PF-04937319 250 mg MR1) | (gvtprtlwtg) = wqljxeitir hwrlljlccq (erokxelqsr, wnupkhnfdc - rzymrkzvex) View more | ||||||
Phase 2 | 639 | obsqznmrcc(sjpndjlwtp) = Hypoglycaemia was reported in 2.5% of patients (on placebo), 5.1% of patients (on PF-04937319 100mg), 1.8% of patients (on sitagliptin) and 34.4% of patients (on titrated glimepiride) ogenrnmmjh (oxtxuyfuxe ) | - | 01 Aug 2015 | |||